Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion.
作者信息
Warden Bruce A, MacKay John, Jafari Melika, Willman Alana, Stecker Eric C
机构信息
1 Department of Pharmacy Oregon Health & Science University Portland OR.
2 Knight Cardiovascular Institute Oregon Health & Science University Portland OR.
出版信息
J Am Heart Assoc. 2018 Nov 20;7(22):e010854. doi: 10.1161/JAHA.118.010854.
PMID:30571504
Abstract
摘要
相似文献
[1]
[2]
Anticoagulants: What is new and what is the standard?
Clin Pharmacol Ther. 2016-8
[3]
Using new oral anticoagulants in patients undergoing major orthopedic surgery.
Curr Rheumatol Rep. 2015-4
[4]
[Not Available].
Lakartidningen. 2018-12-4
[5]
A Review on the New and Old Anticoagulants.
Orthop Nurs. 2019
[6]
[Not Available].
Lakartidningen. 2018-12-4
[7]
Direct oral anticoagulants: An update.
Med Clin (Barc). 2017-12-30
[8]
[9]
Measuring Direct Oral Anticoagulants.
Methods Mol Biol. 2017
[10]
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Intern Emerg Med. 2017-8
引用本文的文献
[1]
[3]
[4]
Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?
Medicina (Kaunas). 2021-5-31
本文引用的文献
[2]
[3]
[4]
[5]
[6]
Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.
Heart Lung Circ. 2018-7
[7]
[8]
[9]
Edoxaban: A direct oral anticoagulant.
Am J Health Syst Pharm. 2017-2-1
[10]
A Comparison Between Dabigatran and Warfarin on Time to Elective Cardioversion.
J Atr Fibrillation. 2016-4-30
Zotero 插件